Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Amortizatization of Intangibles: 2022-2025

Historic Amortizatization of Intangibles for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to -$615,000.

  • Stoke Therapeutics' Amortizatization of Intangibles fell 12.43% to -$615,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.4 million, marking a year-over-year decrease of 43.73%. This contributed to the annual value of -$1.6 million for FY2024, which is 405.23% down from last year.
  • Latest data reveals that Stoke Therapeutics reported Amortizatization of Intangibles of -$615,000 as of Q3 2025, which was down 216.70% from $527,000 recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' Amortizatization of Intangibles registered a high of $527,000 during Q2 2025, and its lowest value of -$782,000 during Q4 2024.
  • Over the past 3 years, Stoke Therapeutics' median Amortizatization of Intangibles value was -$146,000 (recorded in 2023), while the average stood at -$231,727.
  • Examining YoY changes over the last 5 years, Stoke Therapeutics' Amortizatization of Intangibles showed a top increase of 282.35% in 2025 and a maximum decrease of 1,958.33% in 2025.
  • Stoke Therapeutics' Amortizatization of Intangibles (Quarterly) stood at -$151,000 in 2022, then skyrocketed by 41.06% to -$89,000 in 2023, then slumped by 778.65% to -$782,000 in 2024, then declined by 12.43% to -$615,000 in 2025.
  • Its Amortizatization of Intangibles stands at -$615,000 for Q3 2025, versus $527,000 for Q2 2025 and -$494,000 for Q1 2025.